Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Emily Sheldon-Waniga"'
Autor:
Daruka Mahadevan, E. Jane Leonard, Emily Sheldon-Waniga, Xiaofei Zhou, Karthik Venkatakrishnan, Susan Groshen, Catherine Spier, Monika Schmelz, Raul Mena, Ari VanderWalde, Gregory Monohan, Anand Karnad, Steven Weitman, Steven H. Bernstein, Alexandra Stefanovic, Swaminathan Padmanabhan Iyer, Peter Rosen, Soham Puvvada, Jia Ruan, Daniel Persky, John Hayslip, Kevin McDonagh, Steven I. Park, Jonathan W. Friedberg, Kevin R. Kelly
Purpose:The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d62ddf276e9d4e05bedc13051158c0
https://doi.org/10.1158/1078-0432.c.6527549.v1
https://doi.org/10.1158/1078-0432.c.6527549.v1
Autor:
Daruka Mahadevan, E. Jane Leonard, Emily Sheldon-Waniga, Xiaofei Zhou, Karthik Venkatakrishnan, Susan Groshen, Catherine Spier, Monika Schmelz, Raul Mena, Ari VanderWalde, Gregory Monohan, Anand Karnad, Steven Weitman, Steven H. Bernstein, Alexandra Stefanovic, Swaminathan Padmanabhan Iyer, Peter Rosen, Soham Puvvada, Jia Ruan, Daniel Persky, John Hayslip, Kevin McDonagh, Steven I. Park, Jonathan W. Friedberg, Kevin R. Kelly
Immunohistochemical staining of Bcl2, cMyc, Ki67, and CD3 in DLBCL subtype representative tumor samples (same as Supplementary Figure S1). Note that AD091967 is positive for both Bcl2 and cMyc. Cases AB189717, AD550620, and AE575816 show high prolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35dea50caf664733e0b470fbc480a18f
https://doi.org/10.1158/1078-0432.22470386.v1
https://doi.org/10.1158/1078-0432.22470386.v1
Autor:
Emily Sheldon-Waniga, Diane R. Mould, Takatoshi Takubo, Xiaofei Zhou, Karthik Venkatakrishnan, Ashley Milton, Dirk Huebner
Publikováno v:
British Journal of Clinical Pharmacology. 84:35-51
Aims This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. Methods A population pharmacokinetic analysis was per
Autor:
Alberto Chiappori, Huifeng Niu, Hyunjin Shin, Eric Kong, C study investigators, Anne C. Chiang, Jeffrey Ecsedy, Miguel Williams, E. Jane Leonard, Margarita Majem, Zsuzsanna Mark, Christina S. Baik, Cong Li, Jaromír Roubec, Christos Chouaid, Krisztina Czebe, G. Speranza, Lauren Averett Byers, David R. Spigel, Tibor Csoszi, Brittany Bahamon, John Simmons, Sunita Badola, Chandra P. Belani, Edgardo S. Santos, Claudio Dansky Ullmann, Gyula Ostoros, Vitezslav Kolek, Manish R. Patel, Jesus Corral Jaime, Anil Abraham Joy, Lisa Bedford, Emily Sheldon-Waniga, Sian Jones, Kristiaan Nackaerts, Taofeek K. Owonikoko, Matthew Bryant
Publikováno v:
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
INTRODUCTION: We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. METHODS: In this double-blind study, patients with relapsed or refractory SCLC wer
Autor:
Russell J. Schilder, Anne Lesoin, Lainie P. Martin, Razelle Kurzrock, Michel Fabbro, Sharad A. Ghamande, E. Jane Leonard, Alain Lortholary, Isabelle Ray-Coquard, Ursula A. Matulonis, Andrzej Roszak, William P. Tew, Xiaofei Zhou, Linda R. Duska, Joseph Buscema, Karthik Venkatakrishnan, Gerald Steven Falchook, Peter E. Schwartz, Siqing Fu, Emily Sheldon-Waniga, Huamao Mark Lin, Heidi J. Gray, Barbara A. Goff, Kian Behbakht, Robert L. Coleman, Piotr Sawrycki
IMPORTANCE: There is an unmet medical need for the treatment of recurrent ovarian cancer, and new approaches are needed to improve progression-free survival (PFS) and overall survival. OBJECTIVE: This phase 1/2 study evaluated the activity of alisert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9638646354a6502b409da939af67720e
https://europepmc.org/articles/PMC6439781/
https://europepmc.org/articles/PMC6439781/
Autor:
Manish R. Patel, Rakesh Popat, Kate Stumpo, Yaping Shou, J. Perez De Oteyza, Pier Luigi Zinzani, Emily Sheldon-Waniga, Jason B. Kaplan, Ian Chau, John Radford, Alessandro Rambaldi, D. El-Sharkawi, Stephanie Faucette, Francesc Bosch, Swami P. Iyer, Jeffrey R. Infante, Cecilia Carpio, Leo I. Gordon, Giuseppe Gritti, S. Madan
Publikováno v:
Hematological Oncology. 35:72-74
Autor:
Swaminathan P. Iyer, Karthik Venkatakrishnan, Alexandra Stefanovic, Steven H. Bernstein, Jonathan W. Friedberg, E. Jane Leonard, Xiaofei Zhou, Ari M. Vanderwalde, John Hayslip, Raul R. Mena, Soham D. Puvvada, Gregory Monohan, Daruka Mahadevan, Kevin R. Kelly, Jia Ruan, Anand B. Karnad, Emily Sheldon-Waniga, Monika Schmelz, Peter Rosen, Steven I. Park, Susan Groshen, Daniel O. Persky, Steven D. Weitman, Catherine M. Spier, Kevin T. McDonagh
Publikováno v:
Clin Cancer Res
Purpose: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b7c08ea73c1a23e1be920e804e80a6
https://europepmc.org/articles/PMC7731903/
https://europepmc.org/articles/PMC7731903/
Autor:
Dirk Huebner, Claudio Dansky Ullmann, Kristiaan Nackaerts, E. Jane Leonard, David R. Spigel, Gyula Ostoros, Erin Zagadailov, Taofeek K. Owonikoko, Emily Sheldon-Waniga, Christina S. Baik, Tibor Csoszi
Publikováno v:
Journal of Thoracic Oncology. 12:S261-S262
Autor:
Shunsuke Kondo, Yasutoshi Kuboki, Hongmei Li, Xiaofei Zhou, Emily Sheldon-Waniga, Toshihiko Doi, Noboru Yamamoto, Toshio Shimizu, Brittany Bahamon, Hideaki Takahashi
Publikováno v:
Journal of Clinical Oncology. 36:2506-2506
2506Background: TAK-931 is an oral selective inhibitor of CDC7, a protein kinase with key roles in DNA replication and DNA damage response. TAK-931 has demonstrated potent antitumor activity in var...
Autor:
Jason B. Kaplan, Ian Chau, Leo I. Gordon, John Radford, Chin-Hin Ng, Francesc Bosch, Sumit Madan, Rakesh Popat, Pier Luigi Zinzani, Manish R. Patel, Jeffrey R. Infante, Cecilia Carpio, Jaime Pérez de Oteyza, Emily Sheldon-Waniga, Miguel Williams, Giuseppe Gritti, Kate Stumpo, Stephanie Faucette, Alessandro Rambaldi, Yaping Shou
Publikováno v:
Blood. 128:624-624
Background Spleen tyrosine kinase (SYK), a nonreceptor kinase with a key role in B-cell receptor signaling-driven tumorigenesis, is a viable target for inhibition in B-cell malignancies. SYK is also a key regulator of FMS-like tyrosine kinase 3 (FLT-